Chen Ju-mei, Yang Yong-ping, Chen De-yong, Han Jin, Jin Xue-yuan, Huang Ze-xiang, Xu Cheng-bin, Shen Yan-ming
The No. 302 Hospital of the Chinese People's Liberation Army, Beijing 100039, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Dec;21(4):358-60.
To study the clinical therapeutic effects and safety of Fufang Biejia Ruangan tablet (FBRt) in patients with chronic hepatitis B complicated with hepatic fibrosis.
Totally 420 patients were randomly divided into two groups, FBRt group (300 cases) were treated with Fufang Biejia Ruangan tablets and control group (120 cases) were treated with He Luo Shu Gan capsule, the patients in both groups were treated for 6 months.
The cure rate and total effective rate of FBRt group were significantly higher than those of control group (55.67 percent and 81.67 percent vs. 15.8 percent and 60.00 percent, P less than 0.01).
Fufang Biejia Ruangan tablet could alleviate clinical symptoms and hepatic fibrosis. Fufang Biejia Ruangan tablet is effective and safe in treatment of patients with chronic hepatitis B complicated with liver fibrosis.
研究复方鳖甲软肝片（FBRt）治疗慢性乙型肝炎合并肝纤维化患者的临床疗效及安全性。
将420例患者随机分为两组，FBRt组（300例）服用复方鳖甲软肝片，对照组（120例）服用和络舒肝胶囊，两组患者均治疗6个月。
FBRt组的治愈率和总有效率显著高于对照组（55.67%和81.67% vs. 15.8%和60.00%，P<0.01）。
复方鳖甲软肝片可缓解临床症状及肝纤维化。复方鳖甲软肝片治疗慢性乙型肝炎合并肝纤维化患者有效且安全。
